332 ENCINITAS BOULEVARD, ENCINITAS, CA
Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Kiora Pharmaceuticals Increases Share Allocation by 1.5 Million Shares
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Announces Private Placement for Up to $24 Million led by Perceptive Advisors
Announces Management Team Changes
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload